Publications by authors named "Rafael Sergio Aguayo-Ortiz"
Article Synopsis
- - The study analyzed the survival rate and interruption risks of adalimumab (ADA) treatment in 539 adult patients with hidradenitis suppurativa (HS), providing insights before and after the COVID-19 pandemic.
- - Findings revealed that about 39.92% of patients interrupted ADA, with the main reasons being inefficacy (51.69%) and adverse effects (21.35%); ADA showed a median overall drug survival of 56.2 months.
- - Factors like female gender, prolonged HS diagnosis, and higher HS severity correlated with decreased ADA survival, while post-pandemic trends included younger patients starting treatment at a lower HS stage.